ID: ALA3321812

Max Phase: Preclinical

Molecular Formula: C26H19F3N6O2

Molecular Weight: 504.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-n1c(N)c(C(N)=O)c2nc3ccccc3nc21

Standard InChI:  InChI=1S/C26H19F3N6O2/c1-13-9-10-16(32-25(37)14-5-4-6-15(11-14)26(27,28)29)12-19(13)35-22(30)20(23(31)36)21-24(35)34-18-8-3-2-7-17(18)33-21/h2-12H,30H2,1H3,(H2,31,36)(H,32,37)

Standard InChI Key:  PWUCAOOPWHJDPV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 504.47

Molecular Weight (Monoisotopic): 504.1522

AlogP: 4.83

#Rotatable Bonds: 4

Polar Surface Area: 128.92

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.92

CX Basic pKa: 1.00

CX LogP: 5.28

CX LogD: 5.28

Aromatic Rings: 5

Heavy Atoms: 37

QED Weighted: 0.32

Np Likeness Score: -1.69

References

1. Unzue A, Dong J, Lafleur K, Zhao H, Frugier E, Caflisch A, Nevado C..  (2014)  Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.,  57  (15): [PMID:25076195] [10.1021/jm5009242]

Source

Source(1):

• Scientific Literature